CB1 Capital is an investment manager and advisor that specializes in the supply chain of cannabinoid-based wellness solutions, products and therapies that address a wide range of unmet medical conditions, or have commercial use-cases.


It’s not about getting high; it’s about getting well.®


We are building a community of thought-leaders to help solve one of the most amazing riddles in modern medical history: how to unlock the universe of cannabinoid wellness properties from the cannabis plant.

Most cannabinoids are non-euphoric and many of them provide therapeutic benefits. What’s more, they interact with our ECS in ways that are beginning to reshape our understanding of health and wellness.

The endocannabinoid system (ECS) is one of the most ubiquitous networks of receptors in the human body and a retrograde signaling system that helps to regulate neurotransmissions.  

Science is teaching us that by targeting the right receptors with the right cannabinoids, a multitude of wellness indications, applications, and potentially groundbreaking medical breakthroughs are not only plausible—but probable.


This is healthcare disruption. And it’s happening.

We believe cannabis is in the nascent stages of a multi-year efficacy-led bull market and will separate into several categories – consumer packaged goods, including beverages and nutraceuticals, industrial use-cases, such as plastic composites and hempcrete, and efficacy-driven solutions, or biotech.

We believe the collective perception will shift from viewing cannabis as a discretionary vice to one with an abundance of use-cases.

CB1 Capital does not touch the plant or move the plant across state lines; we buy, sell, and invest in securities of publicly traded companies and select private ventures, and advise emerging companies in the space.


Get Updates

Get updates on the latest cannabis related news directly in your e-mail in our Morning Update newsletter.


Our Team


Todd Harrison

Todd Harrison is the Founding Partner of CB1 and our Chief Investment Officer. Todd has spent almost three decades on Wall Street managing risk and researching market strategies. His institutional experience includes Morgan Stanley Global Equity Derivatives (VP), The Galleon Group (MD-Derivatives), and Cramer, Berkowitz LLC (President and Head of Trading). Read Todd’s Full Bio >



Loren Defalco

Loren DeFalco is a Partner of CB1 and our Head of Research. He cured himself of epileptic seizures through a regime of CBD and cannabinoids nine years ago and continued to research ECS through medical journals and scientific developments. His understanding of the ECS system and nutraceutical arena makes him an ideal choice to lead our research efforts. Read Loren’s Full Bio >


Jon Tyras

Jon Tyras is a Partner of CB1 and our Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer. Jon has spent over 20 years in the industry. He was most recently the Chief Financial Officer and General Counsel of the $15 billion public securities platform of Brookfield Asset Management, a leading global alternative asset manager with approximately $250 billion in AUM. Read Jon’s Full Bio >


Josh Felker

Josh Felker is a Research Analyst at CB1 and our resident Canadian market reference. He has written extensively for FelkerInvesting.com, reaching the top pages of Reddit/Google for articles regarding the valuation of Canadian Licensed Producers.


Andrew Pfeffer

Andrew is a Senior Trader at CB1 who works directly with the investment team. Andrew has been in equities for over 20 years. After spending some time on the buy side, Andrew spent 18 years in trading at Virtu Financial and its predecessor firms, a leading market maker and liquidity provider, and was Head of Trading for the Healthcare and Biotech sectors. He has a Bachelor of Arts degree from Cornell University.

Our Advisory Board


Dr. Ethan Russo

Board Certified Neurologist, psychopharmacology researcher; Director of Research & Development, International Cannabis and Cannabinoid Institute (ICCI), former Senior Medical Advisor, GW Pharmaceuticals; former Medical Director, PHYTECS.


Dr. Julie Holland

Psychiatrist and psychopharmacologist, Author of the bestsellers “Weekends at Bellevue” and “Moody Bitches”, editor of “The Pot Book: A Complete Guide to Cannabis”, medical monitor for a clinical study examining the efficacy of using cannabis in the treatment of Post Traumatic Stress Disorder in veterans.


Lorne Gertner

Chairman of HG2 Capital Corp, CEO of Hill & Gertner Capital Group; Co-Founder, The Cronos Group; Director, Emblem Corp.; Co-Founder & Chairman Tokyo Smoke; Investment Partner and Director, Green Acre Capital.


Gov. Gary Johnson

Twenty-ninth governor of New Mexico, two-time Presidential candidate. Founder, Big J Enterprises; Former CEO of Cannabis Sativa, Inc.


Dave Charnick

Subject Matter Expert, Founder, Kalyx Development Inc. and Special Advisor, Cannabis Benchmarks, a division of New Leaf Data Sciences.





What is the Endocannabinoid System? (ECS)

The Endocannabinoid System is a recently discovered biological system comprised of lipid messengers that has receptors lining the entire body.

Cannabinoids (compounds in the cannabis plant) can act on the ECS as regulators of neuro-transmission flow and homeostatic regulators of inflammation in the body.

There are a wide range of diseases affected by the ECS, including cancer and most inflammatory related diseases.

Click here to access research studies by indication/ailment